Literature DB >> 28754191

Biosimilars: an optimistic outlook, but vigilance is needed.

.   

Abstract

Mesh：

Substances：

Year:  2017        PMID： 28754191     DOI： 10.1016/S2352-3026(17)30127-8

Source DB:  PubMed          Journal:  Lancet Haematol        ISSN： 2352-3026            Impact factor:   18.959


× No keyword cloud information.
  4 in total

Review 1.  Anti-CD20 Directed Therapy of B Cell Lymphomas: Are New Agents Really Better?

Authors:  Ciara L Freeman; Laurie Sehn
Journal:  Curr Oncol Rep       Date:  2018-11-27       Impact factor: 5.075

2.  Comparison of the Efficacy of Innovator Rituximab and its Biosimilars in Diffuse Large B Cell Lymphoma Patients: A Retrospective Analysis.

Authors:  Aniket Bankar; Anu Korula; Aby Abraham; Auro Viswabandya; Biju George; Alok Srivastava; Vikram Mathews
Journal:  Indian J Hematol Blood Transfus       Date:  2019-08-06       Impact factor: 0.900

Review 3.  Use of anti-CD20 therapy in follicular and marginal zone lymphoma: a review of the literature.

Authors:  Luis Miguel Juárez-Salcedo; Diego Conde-Royo; Keina Quiroz-Cervantes; Samir Dalia
Journal:  Drugs Context       Date:  2020-05-06

4.  A Generic Model for Follicular Lymphoma: Predicting Cost, Life Expectancy, and Quality-Adjusted-Life-Year Using UK Population-Based Observational Data.

Authors:  Han-I Wang; Eve Roman; Simon Crouch; Eline Aas; Cathy Burton; Russell Patmore; Alexandra Smith
Journal:  Value Health       Date:  2018-04-24       Impact factor: 5.725
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.